We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT00612859
Previous Study | Return to List | Next Study

Study to Assess the Efficacy and Safety of Levetiracetam for the Treatment of Social Anxiety Disorder (Generalized Type)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00612859
Recruitment Status : Completed
First Posted : February 12, 2008
Last Update Posted : November 26, 2013
Information provided by:
UCB Pharma

Brief Summary:
Preclinical and clinical findings indicate that LEV has some anxiolytic potential. There is reason to believe that compounds with anxiolytic activity may have broad clinical utility across the anxiety spectrum. This trial was intended to explore LEV's utility in adults with social anxiety disorder.

Condition or disease Intervention/treatment Phase
Anxiety Disorders Drug: levetiracetam Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 217 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-Blind, PBO-Controlled, Parallel Group Study to Assess the Efficacy and Safety of Levetiracetam Versus PBO for the Treatment of Social Anxiety Disorder (Generalized Type)
Study Start Date : September 2003
Actual Primary Completion Date : June 2004
Actual Study Completion Date : June 2004

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Anxiety

Primary Outcome Measures :
  1. change in Liebowitz Social Anxiety Scale (LSAS) score from Visit 2 to the last Evaluation period visit attended using last observation carried forward (LOCF) methods
  2. Safety: monitoring of AEs, clinical laboratory tests, physical examination and vital signs.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female outpatients between 18 and 70 years old inclusive;
  • symptoms of social anxiety disorders (generalized type) present for at least 1 year prior to Selection Visit;
  • had a score of >=60 on the LSAS at the Selection Visit and at the Randomization Visit. Additionally, the clinician's gloal impression of change score must have been >= 2 at the Randomization Visit;
  • had a telephone where they could be directly contacted.

Exclusion Criteria:

  • History of autism or Asperger's Disease;
  • had another primary axis I disorder or fulfilled diagnostic and statistical manual of mental disorders-4th edition (DSM-IV) criteria in the 6 months prior to Screening;
  • major depression as measured by a Hamilton Depression Rating Scale (HAM-D-17 items) total score of > 17 and/or a suicide subscale score on the HAM-D-17 items of > 2 at the Selection or Randomization Visit;
  • history of electroconvulsive therapy within the prior 3 months;
  • history of psychotherapy which was not stable and ongoing for at least 6 months prior to Visit 1;
  • clinical history of significantly impaired renal function with an estimated creatinine clearance below 80 mL/min;
  • clinically significant medical condition;
  • history of any clinically significant allergic condition or allergy to LEV or pyrrolidone derivatives;
  • neutrophil count of less than 1800/µL.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00612859

Sponsors and Collaborators
UCB Pharma
Layout table for investigator information
Study Director: UCB Clinical Trial Call Center +1 877 822 9493 (UCB)
Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00612859    
Other Study ID Numbers: N01086
First Posted: February 12, 2008    Key Record Dates
Last Update Posted: November 26, 2013
Last Verified: September 2009
Keywords provided by UCB Pharma:
Additional relevant MeSH terms:
Layout table for MeSH terms
Anxiety Disorders
Phobia, Social
Mental Disorders
Phobic Disorders
Nootropic Agents